Center-Authored Papers

Filters: Author is Gilbert, Peter  [Clear All Filters]
2012
Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP et al..  2012.  MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.. PloS one. 7(8):e43396. Abstract
Rolland M, Gilbert P.  2012.  Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.. AIDS research and human retroviruses. 28(4):400-4. Abstract
Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E et al..  2012.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials.. The Journal of infectious diseases. 206(3):431-41. Abstract
Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M et al..  2012.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.. The Lancet infectious diseases. 12(7):531-7. Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L et al..  2012.  Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study).. The Journal of infectious diseases. 206(2):258-266. Abstract
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
2013
Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L et al..  2013.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial.. PloS one. 8(9):e75665. Abstract
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
Fong Y, Sebestyen K, Yu X, Gilbert P, Self S.  2013.  nCal: an R package for non-linear calibration.. Bioinformatics (Oxford, England). Abstract
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Huang Y, Gilbert P et al..  2013.  Reply to richie and villasante.. The Journal of infectious diseases. 207(4):690-2.
Hertz T, Ahmed H, Friedrich DP, Casimiro DR, Self SG, Corey L, McElrath MJ, Buchbinder S, Horton H, Frahm N et al..  2013.  HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.. PLoS pathogens. 9(6):e1003404. Abstract
Liu P, Yates NL, Shen X, Bonsignori M, Moody AM, Liao H-X, Fong Y, Alam MS, Overman GR, Denny T et al..  2013.  Infectious Virion Capture by HIV-1 gp120 Specific IgG from RV144 Vaccinees.. Journal of virology. Abstract
2014
Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, Lundebjerg S, Gilbert P, Van Voorhis WC, Whisler J et al..  2014.  Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge.. PloS one. 9(11):e109654. Abstract
Zolla-Pazner S, Edlefsen PT, Rolland M, Kong X-P, DeCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI et al..  2014.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.. EBioMedicine. 1(1):37-45. Abstract
2015
Vasan S, Rerks-Ngarm S, Gilbert P, Haynes B, Nitayapan S, Pitisuttihum P, Kaewkungwal J, Excler J-L, Robb M, Michael N et al..  2015.  Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection.. Human vaccines & immunotherapeutics. 11(4):1036-7.
Williams WB, Liao H-X, Moody AM, Kepler TB, Alam MS, Gao F, Wiehe K, Trama AM, Jones K, Zhang R et al..  2015.  Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.. Science (New York, N.Y.). Abstract
Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart P-A et al..  2015.  COMPASS identifies T-cell subsets correlated with clinical outcomes.. Nature biotechnology. 33(6):610-6. Abstract
Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, Jaeger FH, Pollara J, Martelli A, Liebl BE et al..  2015.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.. The Journal of clinical investigation. Abstract
Fong Y, Gilbert P.  2015.  Calibration weighted estimation of semiparametric transformation models for two-phase sampling.. Statistics in medicine. 34(10):1695-707. Abstract
2017
Perez LG, Martinez DR, Decamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H et al..  2017.  V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.. PloS one. 12(7):e0180720. Abstract